561 related articles for article (PubMed ID: 27386931)
21. Prognostic significance of the immunoexpression of matrix metalloproteinase MMP2 and its inhibitor TIMP2 in laryngeal cancer.
Danilewicz M; Sikorska B; Wagrowska-Danilewicz M
Med Sci Monit; 2003 Mar; 9(3):MT42-7. PubMed ID: 12640351
[TBL] [Abstract][Full Text] [Related]
22. Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast.
Kim HJ; Park CI; Park BW; Lee HD; Jung WH
Yonsei Med J; 2006 Jun; 47(3):333-42. PubMed ID: 16807982
[TBL] [Abstract][Full Text] [Related]
23. Presence of matrix metalloproteinase-2 and tissue inhibitor matrix metalloproteinase-2 gene polymorphisms and immunohistochemical expressions in intracranial meningiomas.
Coven İ; Ozer O; Ozen O; Şahin Fİ; Altinors N
J Neurosurg; 2014 Dec; 121(6):1478-82. PubMed ID: 25259564
[TBL] [Abstract][Full Text] [Related]
24. Genetic analysis of polymorphisms in biologically relevant candidate genes in patients with abdominal aortic aneurysms.
Ogata T; Shibamura H; Tromp G; Sinha M; Goddard KA; Sakalihasan N; Limet R; MacKean GL; Arthur C; Sueda T; Land S; Kuivaniemi H
J Vasc Surg; 2005 Jun; 41(6):1036-42. PubMed ID: 15944607
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer.
Ross JS; Kaur P; Sheehan CE; Fisher HA; Kaufman RA; Kallakury BV
Mod Pathol; 2003 Mar; 16(3):198-205. PubMed ID: 12640098
[TBL] [Abstract][Full Text] [Related]
26. Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma.
Stokes A; Joutsa J; Ala-Aho R; Pitchers M; Pennington CJ; Martin C; Premachandra DJ; Okada Y; Peltonen J; Grénman R; James HA; Edwards DR; Kähäri VM
Clin Cancer Res; 2010 Apr; 16(7):2022-35. PubMed ID: 20305301
[TBL] [Abstract][Full Text] [Related]
27. MMP, VEGF and TIMP as prognostic factors in recurring bladder cancer.
Wieczorek E; Jablonowski Z; Tomasik B; Konecki T; Jablonska E; Gromadzinska J; Fendler W; Sosnowski M; Wasowicz W; Reszka E
Clin Biochem; 2015 Dec; 48(18):1235-40. PubMed ID: 26197083
[TBL] [Abstract][Full Text] [Related]
28. The Influence of Simvastatin on NGAL, Matrix Metalloproteinases and Their Tissue Inhibitors in Human Intraluminal Thrombus and Abdominal Aortic Aneurysm Tissue.
Piechota-Polanczyk A; Demyanets S; Mittlboeck M; Hofmann M; Domenig CM; Neumayer C; Wojta J; Klinger M; Nanobachvili J; Huk I
Eur J Vasc Endovasc Surg; 2015 May; 49(5):549-55. PubMed ID: 25800096
[TBL] [Abstract][Full Text] [Related]
29. TIMP3 is the primary TIMP to regulate agonist-induced vascular remodelling and hypertension.
Basu R; Lee J; Morton JS; Takawale A; Fan D; Kandalam V; Wang X; Davidge ST; Kassiri Z
Cardiovasc Res; 2013 Jun; 98(3):360-71. PubMed ID: 23524300
[TBL] [Abstract][Full Text] [Related]
30. Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy.
Pritchard SC; Nicolson MC; Lloret C; McKay JA; Ross VG; Kerr KM; Murray GI; McLeod HL
Oncol Rep; 2001; 8(2):421-4. PubMed ID: 11182067
[TBL] [Abstract][Full Text] [Related]
31. [Analysis of TIMP-1, TIMP-2 and TIMP-3 expression as a prognostic factor of laryngeal cancer progression].
Pietruszewska W; Kobos J; Gryczyński M; Durko T; Bojanowska-Poźniak K
Otolaryngol Pol; 2008; 62(4):380-7. PubMed ID: 18837208
[TBL] [Abstract][Full Text] [Related]
32. RT-PCR expression profiling of matrix metalloproteinases and their specific inhibitors in cell lines and fresh biopsies of squamous cell carcinomas of the head and neck.
Dünne AA; Mandic R; Falkenberg S; Dalchow CV; Sesterhenn AM; Werner JA
In Vivo; 2005; 19(5):943-8. PubMed ID: 16097450
[TBL] [Abstract][Full Text] [Related]
33. [Assessment of tissue inhibitor of metalloproteinases-2 (TIMP-2) in laryngeal cancer].
Bojanowska-Poźniak K; Kobos J; Gryczyński M; Durko M; Pietruszewska W
Otolaryngol Pol; 2007; 61(4):612-6. PubMed ID: 18260263
[TBL] [Abstract][Full Text] [Related]
34. TIMP2 and TIMP3 have divergent roles in early renal tubulointerstitial injury.
Wang Z; Famulski K; Lee J; Das SK; Wang X; Halloran P; Oudit GY; Kassiri Z
Kidney Int; 2014 Jan; 85(1):82-93. PubMed ID: 23760282
[TBL] [Abstract][Full Text] [Related]
35. Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring response to adjuvant radiochemotherapy in patients with primary cervical cancer--results of a companion protocol of the randomized NOGGO-AGO phase III clinical trial.
Braicu EI; Gasimli K; Richter R; Nassir M; Kümmel S; Blohmer JU; Yalcinkaya I; Chekerov R; Ignat I; Ionescu A; Mentze M; Fotopoulou C; Pop C; Lichtenegger W; Sehouli J; ;
Anticancer Res; 2014 Jan; 34(1):385-91. PubMed ID: 24403492
[TBL] [Abstract][Full Text] [Related]
36. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma.
Bramhall SR; Neoptolemos JP; Stamp GW; Lemoine NR
J Pathol; 1997 Jul; 182(3):347-55. PubMed ID: 9349239
[TBL] [Abstract][Full Text] [Related]
37. Cyclic AMP-regulated synthesis of the tissue inhibitors of metalloproteinases suppresses the invasive potential of the human fibrosarcoma cell line HT1080.
Tanaka K; Iwamoto Y; Ito Y; Ishibashi T; Nakabeppu Y; Sekiguchi M; Sugioka Y
Cancer Res; 1995 Jul; 55(13):2927-35. PubMed ID: 7796421
[TBL] [Abstract][Full Text] [Related]
38. Concentration of gelatinases and their tissue inhibitors in pancreatic inflammatory and neoplastic tumors and their influence on the early postoperative course.
Lekstan A; Olakowski M; Jabłońska B; Łabuzek K; Olakowska E; Filip I; Lampe P
Pol Przegl Chir; 2013 Feb; 85(2):65-72. PubMed ID: 23585206
[TBL] [Abstract][Full Text] [Related]
39. MMP/TIMP imbalance in amniotic fluid during PROM: an indirect support for endogenous pathway to membrane rupture.
Fortunato SJ; Menon R; Lombardi SJ
J Perinat Med; 1999; 27(5):362-8. PubMed ID: 10642956
[TBL] [Abstract][Full Text] [Related]
40. Expression of the matrix metalloproteases 2, 14, 24, and 25 and tissue inhibitor 3 as potential molecular markers in advanced human gastric cancer.
de la Peña S; Sampieri CL; Ochoa-Lara M; León-Córdoba K; Remes-Troche JM
Dis Markers; 2014; 2014():285906. PubMed ID: 24669030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
